107 related articles for article (PubMed ID: 8679707)
1. Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin.
Chao JC; Wan XS; Engelsberg BN; Rothblum LI; Billings PC
Biochim Biophys Acta; 1996 Jun; 1307(2):213-9. PubMed ID: 8679707
[TBL] [Abstract][Full Text] [Related]
2. Differential binding of HMG1, HMG2, and a single HMG box to cisplatin-damaged DNA.
Farid RS; Bianchi ME; Falciola L; Engelsberg BN; Billings PC
Toxicol Appl Pharmacol; 1996 Dec; 141(2):532-9. PubMed ID: 8975778
[TBL] [Abstract][Full Text] [Related]
3. Analysis of HMG protein binding to DNA modified with the anticancer drug cisplatin.
Cryer JE; Johnson SW; Engelsberg BN; Billings PC
Cancer Chemother Pharmacol; 1996; 38(2):163-8. PubMed ID: 8616907
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
Zhai X; Beckmann H; Jantzen HM; Essigmann JM
Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
[TBL] [Abstract][Full Text] [Related]
5. Characterization of high mobility group protein binding to cisplatin-damaged DNA.
Billings PC; Davis RJ; Engelsberg BN; Skov KA; Hughes EN
Biochem Biophys Res Commun; 1992 Nov; 188(3):1286-94. PubMed ID: 1445361
[TBL] [Abstract][Full Text] [Related]
6. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
Chow CS; Barnes CM; Lippard SJ
Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709
[TBL] [Abstract][Full Text] [Related]
7. Recognition and repair of DNA-cisplatin adducts.
Woźniak K; Błasiak J
Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
[TBL] [Abstract][Full Text] [Related]
8. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
Huang JC; Zamble DB; Reardon JT; Lippard SJ; Sancar A
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10394-8. PubMed ID: 7937961
[TBL] [Abstract][Full Text] [Related]
9. Localization of the binding region of high mobility group protein 2 to cisplatin-damaged DNA.
Lawrence DL; Engelsberg BN; Farid RS; Hughes EN; Billings PC
J Biol Chem; 1993 Nov; 268(32):23940-5. PubMed ID: 8226934
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells.
Arioka H; Nishio K; Ishida T; Fukumoto H; Fukuoka K; Nomoto T; Kurokawa H; Yokote H; Abe S; Saijo N
Jpn J Cancer Res; 1999 Jan; 90(1):108-15. PubMed ID: 10076573
[TBL] [Abstract][Full Text] [Related]
11. Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B.
Jamieson ER; Jacobson MP; Barnes CM; Chow CS; Lippard SJ
J Biol Chem; 1999 Apr; 274(18):12346-54. PubMed ID: 10212205
[TBL] [Abstract][Full Text] [Related]
12. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
[TBL] [Abstract][Full Text] [Related]
13. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo.
McA'Nulty MM; Whitehead JP; Lippard SJ
Biochemistry; 1996 May; 35(19):6089-99. PubMed ID: 8634251
[TBL] [Abstract][Full Text] [Related]
14. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts.
Ohndorf UM; Whitehead JP; Raju NL; Lippard SJ
Biochemistry; 1997 Dec; 36(48):14807-15. PubMed ID: 9398202
[TBL] [Abstract][Full Text] [Related]
15. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ
Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126
[TBL] [Abstract][Full Text] [Related]
16. Upstream binding factor up-regulated in hepatocellular carcinoma is related to the survival and cisplatin-sensitivity of cancer cells.
Huang R; Wu T; Xu L; Liu A; Ji Y; Hu G
FASEB J; 2002 Mar; 16(3):293-301. PubMed ID: 11874979
[TBL] [Abstract][Full Text] [Related]
17. The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity.
Pasheva EA; Ugrinova I; Spassovska NC; Pashev IG
Int J Biochem Cell Biol; 2002 Jan; 34(1):87-92. PubMed ID: 11733188
[TBL] [Abstract][Full Text] [Related]
18. Recognition of cisplatin adducts by cellular proteins.
Kartalou M; Essigmann JM
Mutat Res; 2001 Jul; 478(1-2):1-21. PubMed ID: 11406166
[TBL] [Abstract][Full Text] [Related]
19. Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts.
De Pooter CM; Van Oosterom AT; Scalliet PG; Maes RA; de Bruijn EA
Biochem Pharmacol; 1996 Mar; 51(5):629-34. PubMed ID: 8615899
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin inhibits synthesis of ribosomal RNA in vivo.
Jordan P; Carmo-Fonseca M
Nucleic Acids Res; 1998 Jun; 26(12):2831-6. PubMed ID: 9611224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
